These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 16575257)

  • 1. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
    Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and properties of clots from fibrinogen Bicêtre II (gamma 308 Asn-->Lys). Increased permeability due to larger pores, thicker fibers, and decreased rigidity.
    Marchi R; Loyau S; Anglés-Cano E; Weisel JW
    Ann N Y Acad Sci; 2001; 936():125-8. PubMed ID: 11460469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mutation (deletion of Aalpha-Asn 80) in an abnormal fibrinogen: fibrinogen Caracas VI. Consequences of disruption of the coiled coil for the polymerization of fibrin: peculiar clot structure and diminished stiffness of the clot.
    Marchi RC; Meyer MH; de Bosch NB; Arocha-Piñango CL; Weisel JW
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):559-67. PubMed ID: 15389122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical characterization of fibrinogen Caracas I with an Aalpha-chain truncation at Aalpha-466 Ser: identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen.
    Marchi R; Meyer M; de Bosch N; Soria J; Arocha-Piñango CL; Weisel JW
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):285-93. PubMed ID: 15166913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen.
    Kotlín R; Reicheltová Z; Malý M; Suttnar J; Sobotková A; Salaj P; Hirmerová J; Riedel T; Dyr JE
    Thromb Haemost; 2009 Sep; 102(3):479-86. PubMed ID: 19718467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Caracas I: a dysfibrinogenemia with a hemorrhagic diathesis associated with diminished fibrin fiber diameter and reduced fibrin gel porosity.
    Marchi R; Lundberg U; de Bosch NB; Arocha-Piñango CL
    Blood Coagul Fibrinolysis; 1998 Nov; 9(8):733-9. PubMed ID: 9890716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the gamma-chain.
    Furlan M; Stucki B; Steinmann C; Jungo M; Lämmle B
    Thromb Haemost; 1996 Sep; 76(3):377-83. PubMed ID: 8883274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Matsumoto III: a variant with gamma275 Arg-->Cys (CGC-->TGC)--comparison of fibrin polymerization properties with those of Matsumoto I (gamma364 Asp-->His) and Matsumoto II (gamma308 Asn-->Lys).
    Terasawa F; Okumura N; Higuchi Y; Ishikawa S; Tozuka M; Ishida F; Kitano K; Katsuyama T
    Thromb Haemost; 1999 May; 81(5):763-6. PubMed ID: 10365751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.
    Flood VH; Nagaswami C; Chernysh IN; Al-Mondhiry HA; Weisel JW; Farrell DH
    Br J Haematol; 2007 Jul; 138(1):117-24. PubMed ID: 17555455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic dysfibrinogenemia. Fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability.
    Marchi R; Mirshahi SS; Soria C; Mirshahi M; Zohar M; Collet JP; de Bosch NB; Arocha-Piñango CL; Soria J
    Thromb Res; 2000 Jul; 99(2):187-93. PubMed ID: 10946093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
    Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.
    Flood VH; Al-Mondhiry HA; Farrell DH
    Br J Haematol; 2006 Jul; 134(2):220-6. PubMed ID: 16846481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA).
    Marchi R; Carvajal Z; Meyer M; Soria J; Ruiz-Saez A; Arocha-Piñango CL; Weisel JW
    Thromb Res; 2006; 118(5):637-50. PubMed ID: 16406498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
    Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
    Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
    Marchi R; Lundberg U; Grimbergen J; Koopman J; Torres A; de Bosch NB; Haverkate F; Arocha Piñango CL
    Thromb Haemost; 2000 Aug; 84(2):263-70. PubMed ID: 10959699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of additional carbohydrate in the coiled-coil region of fibrinogen on polymerization and clot structure and properties: characterization of the homozygous and heterozygous forms of fibrinogen Lima (Aalpha Arg141-->Ser with extra glycosylation).
    Marchi R; Arocha-Piñango CL; Nagy H; Matsuda M; Weisel JW
    J Thromb Haemost; 2004 Jun; 2(6):940-8. PubMed ID: 15140130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that fibrinogen γ' directly interferes with protofibril growth: implications for fibrin structure and clot stiffness.
    Allan P; Uitte de Willige S; Abou-Saleh RH; Connell SD; Ariëns RA
    J Thromb Haemost; 2012 Jun; 10(6):1072-80. PubMed ID: 22463367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen Krakow: a novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function.
    Undas A; Zdziarska J; Iwaniec T; Stepien E; Skotnicki AB; de Moerloose P; Neerman-Arbez M
    Thromb Haemost; 2009 May; 101(5):975-6. PubMed ID: 19404553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.